4/2
04:10 pm
atxs
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
3/12
09:12 am
atxs
Astria Therapeutics, Inc. (NASDAQ: ATXS) had its "outperform" rating re-affirmed by analysts at Wedbush.
Medium
Report
Astria Therapeutics, Inc. (NASDAQ: ATXS) had its "outperform" rating re-affirmed by analysts at Wedbush.
3/11
01:27 pm
atxs
Astria Therapeutics, Inc. (NASDAQ: ATXS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $16.00 price target on the stock.
Medium
Report
Astria Therapeutics, Inc. (NASDAQ: ATXS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $16.00 price target on the stock.
3/11
08:13 am
atxs
Astria Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Corporate Update [Yahoo! Finance]
High
Report
Astria Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Corporate Update [Yahoo! Finance]
3/11
08:00 am
atxs
Astria Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Corporate Update
High
Report
Astria Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Corporate Update
3/4
04:10 pm
atxs
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2/28
05:55 am
atxs
Astria commences Phase III hereditary angioedema therapy trial [Yahoo! Finance]
Low
Report
Astria commences Phase III hereditary angioedema therapy trial [Yahoo! Finance]
2/27
12:38 pm
atxs
Astria Therapeutics, Inc. (NASDAQ: ATXS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $16.00 price target on the stock.
Low
Report
Astria Therapeutics, Inc. (NASDAQ: ATXS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $16.00 price target on the stock.
2/27
08:32 am
atxs
Astria Therapeutics Initiates ALPHA-ORBIT Phase 3 Pivotal Trial of Navenibart in Hereditary Angioedema [Yahoo! Finance]
Medium
Report
Astria Therapeutics Initiates ALPHA-ORBIT Phase 3 Pivotal Trial of Navenibart in Hereditary Angioedema [Yahoo! Finance]
2/27
08:00 am
atxs
Astria Therapeutics Initiates ALPHA-ORBIT Phase 3 Pivotal Trial of Navenibart in Hereditary Angioedema
Low
Report
Astria Therapeutics Initiates ALPHA-ORBIT Phase 3 Pivotal Trial of Navenibart in Hereditary Angioedema
2/25
08:00 am
atxs
Astria Therapeutics to Present at Upcoming TD Cowen 45th Annual Health Care Conference
High
Report
Astria Therapeutics to Present at Upcoming TD Cowen 45th Annual Health Care Conference
2/22
09:59 pm
atxs
Calculating The Intrinsic Value Of Astria Therapeutics, Inc. (NASDAQ:ATXS) [Yahoo! Finance]
Medium
Report
Calculating The Intrinsic Value Of Astria Therapeutics, Inc. (NASDAQ:ATXS) [Yahoo! Finance]
2/20
08:19 am
atxs
Astria Therapeutics to Present at Upcoming American Academy of Allergy, Asthma and Immunology and World Allergy Organization Joint Congress [Yahoo! Finance]
High
Report
Astria Therapeutics to Present at Upcoming American Academy of Allergy, Asthma and Immunology and World Allergy Organization Joint Congress [Yahoo! Finance]
2/20
08:00 am
atxs
Astria Therapeutics to Present at Upcoming American Academy of Allergy, Asthma and Immunology and World Allergy Organization Joint Congress
High
Report
Astria Therapeutics to Present at Upcoming American Academy of Allergy, Asthma and Immunology and World Allergy Organization Joint Congress
2/4
04:10 pm
atxs
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2/4
08:37 am
atxs
Astria Therapeutics to Present at Upcoming Oppenheimer 35th Annual Healthcare Life Sciences Conference [Yahoo! Finance]
Low
Report
Astria Therapeutics to Present at Upcoming Oppenheimer 35th Annual Healthcare Life Sciences Conference [Yahoo! Finance]
2/4
08:00 am
atxs
Astria Therapeutics to Present at Upcoming Oppenheimer 35th Annual Healthcare Life Sciences Conference
Medium
Report
Astria Therapeutics to Present at Upcoming Oppenheimer 35th Annual Healthcare Life Sciences Conference
2/3
08:36 am
atxs
Astria Therapeutics to Present at Upcoming Western Society of Allergy, Asthma & Immunology Annual Scientific Session [Yahoo! Finance]
Low
Report
Astria Therapeutics to Present at Upcoming Western Society of Allergy, Asthma & Immunology Annual Scientific Session [Yahoo! Finance]
2/3
08:00 am
atxs
Astria Therapeutics to Present at Upcoming Western Society of Allergy, Asthma & Immunology Annual Scientific Session
Medium
Report
Astria Therapeutics to Present at Upcoming Western Society of Allergy, Asthma & Immunology Annual Scientific Session
2/1
05:58 am
atxs
Astria Therapeutics, Inc. (NASDAQ: ATXS) was upgraded by analysts at Citizens Jmp to a "strong-buy" rating.
Medium
Report
Astria Therapeutics, Inc. (NASDAQ: ATXS) was upgraded by analysts at Citizens Jmp to a "strong-buy" rating.
1/31
07:33 am
atxs
Astria Therapeutics, Inc. (NASDAQ: ATXS) is now covered by analysts at JMP Securities. They set an "outperform" rating and a $26.00 price target on the stock.
Low
Report
Astria Therapeutics, Inc. (NASDAQ: ATXS) is now covered by analysts at JMP Securities. They set an "outperform" rating and a $26.00 price target on the stock.
1/23
12:50 pm
atxs
Astria Therapeutics, Inc. (NASDAQ: ATXS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $16.00 price target on the stock.
Low
Report
Astria Therapeutics, Inc. (NASDAQ: ATXS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $16.00 price target on the stock.
1/23
08:00 am
atxs
Astria Therapeutics Announces Initiation of Phase 1a Trial of STAR-0310, a Potential Best-in-Class Monoclonal Antibody OX40 Antagonist for the Treatment of Atopic Dermatitis
Neutral
Report
Astria Therapeutics Announces Initiation of Phase 1a Trial of STAR-0310, a Potential Best-in-Class Monoclonal Antibody OX40 Antagonist for the Treatment of Atopic Dermatitis
1/13
10:58 am
atxs
Astria Therapeutics, Inc. (NASDAQ: ATXS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $16.00 price target on the stock.
Low
Report
Astria Therapeutics, Inc. (NASDAQ: ATXS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $16.00 price target on the stock.
1/13
08:00 am
atxs
Astria Therapeutics Announces Design of ALPHA-ORBIT Pivotal Phase 3 Trial of Navenibart in HAE
Medium
Report
Astria Therapeutics Announces Design of ALPHA-ORBIT Pivotal Phase 3 Trial of Navenibart in HAE